Covaxin, an Indian indigenous coronavirus vaccine developed by Hyderabad-based Bharat Biotech, has reportedly reduced the number of Phase II trial volunteers by half. The Oxford-AstraZeneca coronavirus vaccine, meanwhile, is being studied in phase III studies.
On the other hand , the World Bank has promised $12 billion to support the funding of coronavirus vaccines by developed nations and to support the care of their citizens.
Up to now, two of the main Covid-19 vaccine candidates have experienced setbacks among volunteers with illnesses, with the latest being Johnson & Johnson since the September pause of AstraZeneca.
According to a CNBC-TV18 report, Indian vaccine manufacturer Bharat Biotech has decided to cut the number of volunteers for the Phase II clinical trials of the candidate for coronavirus vaccine Covaxin by half.
The study said that 750 volunteers were enrolled by Bharat Biotech for the Covaxin trials, but now the number has been reduced to 380. It has also reduced the number of vaccine trial sites.
With over 350 volunteers, Bharat Biotech completed the Phase I trials and is now in the second phase. The researchers maintained that during the testing of the Covid-19 vaccine candidate, the studies have not yet suffered any major illness or setback.
Meanwhile, in its latest report, the Ministry of Health has said that Covaxin will reach Phase III trials soon and is on its way. By 2021, and possibly from more than one source, India will receive a Covid-19 vaccine from the state.
Bharat Biotech, which had demanded DCGI’s nod for conducting its Covid-19 vaccine candidate’s Phase III clinical trials, was asked to send complete safety and immunogenicity data from the ongoing Phase II study ,in addition to offering some clarifications, before moving to the next phase.
Currently, the coronavirus vaccine candidate developed by drugmaker AstraZeneca and Oxford University is in the third phase of worldwide clinical trials. In India, where the trials are being performed by the Serum Institute of India (SII) is leading the process in several cities across the world, including Pune, Bhubaneshwar, Chandigarh.
The Ministry of Health said the AstraZeneca-Oxford vaccine Phase III trials are underway and results are expected about November-December.
The Indian Serum Institute, which has collaborated with AstraZeneca to develop the Oxford Covid-19 vaccine candidate, is conducting clinical human antidote phase II and phase III trials in India.
One of the most advanced candidates in the race against the novel coronavirus is being touted by AstraZeneca ‘s experimental Covid-19 vaccine. It is one of the candidates for the most awaited vaccine in the world. Following a brief setback in September, trials across countries for the Oxford-AstraZeneca vaccine candidate have resumed.
In order to produce an immune response and avoid infection, the coronavirus vaccine uses a weakened variant of a chimpanzee common cold virus that codes instructions for producing proteins from the novel coronavirus.
Zydus Cadila Ltd is investigating the Covid-19 vaccine candidate in phase II of human clinical trials. The second indigenous vaccine is being made by the Gujarat-based pharma giant and is currently testing the antidote on volunteers for the Phase II trials.
Also read: Delhi Doctors On Strike Over Unpaid Salary